CRT 2026

Panel Discussion With Questions & Answers

Moderator(s)

• 

  Marc Cohen, MD

  Chair of Medicine
  Newark Beth Israel Med Ctr
  Philadelphia, Pennsylvania, United States

  Disclosure(s): BSC, Amgen, BCRI, PERC, NAMSA, BMS, Janssen, Regeneron: Grant/Research Support (Ongoing)
• 

  C. Michael Gibson, MD

  Professor of Medicine
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure(s): Amgen, Chiesi, Angel/Avertix Medical, Anthos Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Bayer Corporation, Corsear, MashUp MD, Bioclinica, MD Magazine, Boehringer Ingelheim, Merck, Boston Clinical Research Institute, MjHeal: Consulting Fees (e.g., advisory boards) (Ongoing); HeartBeam, nference, Flow Therapy, Celecor, Fortress Biotech, TribeMD (Co-Founder), Generable and Lexaria: Stock Options [in privately held companies] (Ongoing); Johnson & Johnson Corporation, CSL Behring, SCAD Alliance, NACAM Trial (Sub-award - 5R01HL151996-05), and Janssen Pharmaceuticals.: Grant/Research Support (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing)
• 

  Neal S. Kleiman, MD, FACC, MSCAI

  Medical Director, Cardiac Catheterization Laboratories
  Houston Methodist DeBakey Heart and Vascular Center
  Houston, Texas, United States

  Disclosure(s): Abbott Vascular, Medtronic, Boston Scientific: Grant/Research Support (Ongoing)

Panel Discussant(s)

• 

  Sukhdeep S. Bhogal, MD

  Interventional Cardiologist
  Sovah Health
  Roanoke, Virginia, United States

  Disclosure(s): No financial relationships to disclose
• 

  Michael J. Lipinski, MD, PhD

  Interventional Cardiologist
  Lee Health Heart Institute
  Fort Myers, Florida, United States

  Disclosure(s): Pfizer: Stock-publicly held company (excluding mutual/index funds) (Ongoing); Sanofi/Genzyme: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); United Healthcare: Stock-publicly held company (excluding mutual/index funds) (Ongoing)
• 

  Robert S. Rosenson, MD

  Director of Metabolism and Lipids
  Mount Sinai Health System
  New York, New York, United States

  Disclosure(s): 89Bio: Grant/Research Support (Ongoing); Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AstraZeneca Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Kowa Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); NIH: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharma: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Wolters Kluwer Pharma: Royalties (Ongoing)
• JR

  Jennifer Rymer, MD

  Interventional cardiologist
  Duke, North Carolina, United States

  Disclosure information not submitted.
• 

  Tiziana Claudia Aranzulla, MD, MSc

  Interventional cardiology
  A.O. Ordine Mauriziano di Torino
  Turin, Italy

  Disclosure(s): No financial relationships to disclose